**Dare Bioscience, Inc. Announces 2025 Financial Results and Strategic Developments**

Dare Bioscience, Inc., a women's health biotech company, reported its financial results for the year ended December 31, 2025, showcasing a revenue of $1.03 million, a significant increase from the $9,784 reported in 2024. This surge in revenue was primarily attributed to a $1.0 million license fee recognized upon the termination of a license agreement with Bayer. However, the company's operating expenses remained substantial at $14.29 million, leading to a loss from operations of $13.55 million. Despite the revenue increase, the net loss for 2025 was $13.40 million, a considerable increase from the $4.05 million net loss in the previous year, primarily due to the absence of a $20.38 million gain from the sale of royalty and milestone rights that occurred in 2024.

The company's strategic shift towards a dual-path approach, incorporating both traditional FDA approval pathways and Section 503B compounding, has led to the commercialization of DARE to PLAY Sildenafil Cream. While the product is available for pre-order fulfillment, revenue from sales is expected to commence in the second quarter of 2026. The company has also invested approximately $1.0 million in the launch of DARE to PLAY, focusing on technology transfer, awareness campaigns, and facilitating access for healthcare providers and women. Furthermore, Dare Bioscience is targeting an early 2027 launch for DARE to RECLAIM estradiol progesterone intravaginal ring, also through Section 503B compounding.

Operationally, Dare Bioscience is advancing its clinical-stage programs, with Ovaprene currently in a pivotal Phase 3 clinical study. The company is also preparing for a Phase 3 study of Sildenafil Cream, contingent upon further feedback from the FDA and securing the necessary capital. The company's research and development expenses were $5.52 million, a decrease from $14.31 million in 2024, primarily due to increased grant funding and decreased manufacturing costs for Ovaprene. As of March 25, 2026, the company had 24 employees, with a focus on leveraging consultants for specialized expertise.

Looking ahead, Dare Bioscience anticipates continued investment in research and development, particularly for Ovaprene, DARE-LARC1, and DARE-HPV, with the latter two supported by non-dilutive funding. The company's ability to execute its business strategy and achieve profitability remains dependent on securing additional capital, navigating regulatory pathways, and successfully commercializing its product candidates. As of March 25, 2026, there were 14,559,502 shares of the company's common stock outstanding.

About Dare Bioscience, Inc.

Dare Bioscience Inc. develops innovative women’s health solutions, including prescription and compounded products for contraception, sexual health, menopause, and vaginal health. Its portfolio features FDA-approved XACIATO for bacterial vaginosis and pipeline candidates like Ovaprene, Sildenafil Cream, and DARE-HRT1, targeting unmet needs in fertility, VMS, and FSAD. The company leverages clinical data, strategic collaborations, and alternative pathways to bring evidence-based, first-in-category products to market.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.